• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

阐明慢性肾脏病与高血压之间的复杂相互作用。

Elucidating the complex interplay between chronic kidney disease and hypertension.

作者信息

Nagata Daisuke, Hishida Erika

机构信息

Division of Nephrology, Department of Internal Medicine, Jichi Medical University, Departments of Internal Medicine, Division of Nephrology, Tochigi, Japan.

出版信息

Hypertens Res. 2024 Dec;47(12):3409-3422. doi: 10.1038/s41440-024-01937-8. Epub 2024 Oct 16.

DOI:10.1038/s41440-024-01937-8
PMID:39415028
Abstract

Chronic kidney disease (CKD) and hypertension share a complex relationship, each exacerbating the progression of the other. CKD contributes to hypertension by decreasing renal function, leading to fluid retention and increased plasma volume, whereas hypertension exacerbates CKD by increasing glomerular pressure and causing renal damage. This review examines the intertwined nature of CKD and hypertension, exploring the factors driving hypertension in CKD and how hypertension accelerates CKD progression. It discusses the role of the renin-angiotensin system and inflammatory cytokines in this relationship, as well as the potential of blood pressure management to slow renal decline. While studies suggest that meticulous blood pressure control can help attenuate CKD progression, optimal management strategies remain unclear and require further investigation. This review also evaluates the evidence surrounding strict antihypertensive therapy in patients with CKD, considering both diabetic and non-diabetic cases. It recommends blood pressure targets based on CKD stage and presence of diabetes, emphasizing the importance of individualized treatment approaches. Renin-angiotensin system inhibitors are highlighted as a key pharmacological intervention due to their renal protective effects, particularly in patients with CKD with proteinuria. However, evidence regarding their efficacy in patients with CKD but without proteinuria is inconclusive. This review underscores the need for comprehensive approaches to effectively address the intertwined nature of CKD and hypertension and calls for further research to optimize clinical management strategies in this complex interplay.

摘要

慢性肾脏病(CKD)与高血压之间存在复杂的关系,二者相互促进对方的进展。CKD通过降低肾功能导致液体潴留和血浆量增加,从而引发高血压,而高血压则通过增加肾小球压力和造成肾损伤来加重CKD。本综述探讨了CKD与高血压的相互交织的本质,探究了CKD中导致高血压的因素以及高血压如何加速CKD进展。它讨论了肾素 - 血管紧张素系统和炎性细胞因子在这种关系中的作用,以及血压管理减缓肾脏衰退的潜力。虽然研究表明,严格控制血压有助于减轻CKD进展,但最佳管理策略仍不明确,需要进一步研究。本综述还评估了CKD患者严格抗高血压治疗的相关证据,同时考虑了糖尿病和非糖尿病病例。它根据CKD阶段和糖尿病的存在情况推荐了血压目标,强调了个体化治疗方法的重要性。肾素 -血管紧张素系统抑制剂因其肾脏保护作用而被视为关键的药物干预措施,特别是在伴有蛋白尿的CKD患者中。然而,关于其在无蛋白尿的CKD患者中的疗效证据尚无定论。本综述强调需要采取综合方法来有效应对CKD与高血压的相互交织的本质,并呼吁进一步研究以优化这种复杂相互作用中的临床管理策略。

相似文献

1
Elucidating the complex interplay between chronic kidney disease and hypertension.阐明慢性肾脏病与高血压之间的复杂相互作用。
Hypertens Res. 2024 Dec;47(12):3409-3422. doi: 10.1038/s41440-024-01937-8. Epub 2024 Oct 16.
2
The effect of renin-angiotensin-aldosterone system blockers on the progression of chronic kidney disease in hypertensive elderly patients without proteinuria: PROERCAN study. Rationale and design.血管紧张素-肾素-醛固酮系统阻滞剂对无蛋白尿的老年高血压患者慢性肾脏病进展的影响:PROERCAN 研究。原理和设计。
Hipertens Riesgo Vasc. 2020 Jul-Sep;37(3):101-107. doi: 10.1016/j.hipert.2020.02.005. Epub 2020 Mar 8.
3
Hypertension in Chronic Kidney Disease: Novel Insights.慢性肾脏病中的高血压:新见解
Curr Hypertens Rev. 2020;16(1):45-54. doi: 10.2174/1573402115666190415153554.
4
Questioning the renoprotective role of L-type calcium channel blockers in chronic kidney disease using physiological modeling.运用生理学模型质疑 L 型钙通道阻滞剂在慢性肾病中的肾保护作用。
Am J Physiol Renal Physiol. 2021 Oct 1;321(4):F548-F557. doi: 10.1152/ajprenal.00233.2021. Epub 2021 Sep 6.
5
[New aspects of hypertension management in patients with chronic kidney disease].[慢性肾脏病患者高血压管理的新进展]
Rev Med Suisse. 2014 Sep 10;10(441):1668-72.
6
Revisiting Hypertension Treatment in Patients With Chronic Kidney Disease.重新审视慢性肾脏病患者的高血压治疗。
Semin Nephrol. 2024 Mar;44(2):151514. doi: 10.1016/j.semnephrol.2024.151514. Epub 2024 May 11.
7
Hypertension in children with chronic kidney disease.慢性肾病患儿的高血压
Adv Chronic Kidney Dis. 2005 Oct;12(4):378-84. doi: 10.1053/j.ackd.2005.07.002.
8
Renal protection with angiotensin receptor blockers: where do we stand.血管紧张素受体阻滞剂的肾脏保护作用:我们处于什么位置。
J Nephrol. 2011 Sep-Oct;24(5):569-80. doi: 10.5301/JN.2011.6445.
9
Managing kidney disease with blood-pressure control.控制血压以管理肾病。
Nat Rev Nephrol. 2011 Jun 21;7(8):434-44. doi: 10.1038/nrneph.2011.73.
10
Renin-angiotensin system inhibitors in hypertensive adults with non-diabetic CKD with or without proteinuria: a systematic review and meta-analysis of randomized trials.肾素-血管紧张素系统抑制剂在伴有或不伴有蛋白尿的非糖尿病慢性肾脏病的高血压成人中的应用:一项随机试验的系统评价和荟萃分析。
Hypertens Res. 2019 Apr;42(4):469-482. doi: 10.1038/s41440-018-0116-3. Epub 2019 Apr 5.

引用本文的文献

1
Circulating growth differentiation factor-15 concentration and hypertension risk: a dose-response meta-analysis.循环生长分化因子-15浓度与高血压风险:一项剂量反应荟萃分析。
Front Cardiovasc Med. 2025 Apr 30;12:1500882. doi: 10.3389/fcvm.2025.1500882. eCollection 2025.
2
Effect of N-Acetylcysteine in Mitochondrial Function, Redox Signaling, and Sirtuin 3 Levels in the Heart During Cardiorenal Syndrome Type 4 Development.N-乙酰半胱氨酸对4型心肾综合征发展过程中心脏线粒体功能、氧化还原信号传导及沉默调节蛋白3水平的影响
Antioxidants (Basel). 2025 Mar 20;14(3):367. doi: 10.3390/antiox14030367.
3
Beneficial Effects of Butyrate on Kidney Disease.

本文引用的文献

1
Relationship between the lower limit of systolic blood pressure target and kidney function decline in advanced chronic kidney disease: an instrumental variable analysis from the REACH-J CKD cohort study.晚期慢性肾脏病中收缩压目标下限与肾功能下降的关系:来自 REACH-J CKD 队列研究的工具变量分析。
Hypertens Res. 2023 Nov;46(11):2478-2487. doi: 10.1038/s41440-023-01358-z. Epub 2023 Jul 18.
2
IFN- Contributes to the Immune Mechanisms of Hypertension.IFN- 有助于高血压的免疫机制。
Kidney360. 2022 Oct 26;3(12):2164-2173. doi: 10.34067/KID.0001292022. eCollection 2022 Dec 29.
3
Renin-Angiotensin System Inhibition in Advanced Chronic Kidney Disease.
丁酸盐对肾脏疾病的有益作用。
Nutrients. 2025 Feb 22;17(5):772. doi: 10.3390/nu17050772.
肾素-血管紧张素系统抑制在晚期慢性肾脏病中的应用。
N Engl J Med. 2022 Dec 1;387(22):2021-2032. doi: 10.1056/NEJMoa2210639. Epub 2022 Nov 3.
4
Aldosterone, Mineralocorticoid Receptor Activation, and CKD: A Review of Evolving Treatment Paradigms.醛固酮、盐皮质激素受体激活与慢性肾脏病:不断演变的治疗模式述评。
Am J Kidney Dis. 2022 Nov;80(5):658-666. doi: 10.1053/j.ajkd.2022.04.016. Epub 2022 Sep 1.
5
The IFNγ-PDL1 Pathway Enhances CD8T-DCT Interaction to Promote Hypertension.IFNγ-PDL1 通路增强 CD8T-DCT 相互作用,促进高血压。
Circ Res. 2022 May 13;130(10):1550-1564. doi: 10.1161/CIRCRESAHA.121.320373. Epub 2022 Apr 18.
6
Final Report of a Trial of Intensive versus Standard Blood-Pressure Control.强化与标准血压控制的试验最终报告。
N Engl J Med. 2021 May 20;384(20):1921-1930. doi: 10.1056/NEJMoa1901281.
7
Stopping Renin-Angiotensin System Inhibitors in Patients with Advanced CKD and Risk of Adverse Outcomes: A Nationwide Study.在伴有晚期 CKD 风险的患者中停用肾素-血管紧张素系统抑制剂:一项全国性研究。
J Am Soc Nephrol. 2021 Feb;32(2):424-435. doi: 10.1681/ASN.2020050682. Epub 2020 Dec 28.
8
Practical Strategy for Treating Chronic Kidney Disease (CKD)-Associated with Hypertension.治疗与高血压相关的慢性肾脏病(CKD)的实用策略
Int J Nephrol Renovasc Dis. 2020 Jul 7;13:171-178. doi: 10.2147/IJNRD.S259931. eCollection 2020.
9
Renal Effects of Cytokines in Hypertension.高血压中细胞因子的肾脏效应。
Adv Exp Med Biol. 2019;1165:443-454. doi: 10.1007/978-981-13-8871-2_21.
10
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019).日本高血压学会高血压管理指南(JSH 2019)。
Hypertens Res. 2019 Sep;42(9):1235-1481. doi: 10.1038/s41440-019-0284-9.